Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON (JNJ)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Johnson & Johnson : Health Systems Can Lower Operational Costs and Reduce Environmental Impact with CareAdvantage from the Johnson & Johnson Medical Devices Companies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 05:32pm CEST

By a News Reporter-Staff News Editor at Ecology, Environment & Conservation -- With health systems focused on finding new ways to address their impact on the environment and reduce costs, CareAdvantage from the Johnson & Johnson Medical Devices Companies* now has a new Sustainability capability. Designed to help health systems achieve specific environmental, waste management, cost savings, and sustainable purchasing goals, this offering from the Johnson & Johnson Medical Devices Companies (JJMDC)* * draws on more than 25 years of sustainability commitments by the Johnson & Johnson Family of Companies, including its leadership in medical device reprocessing and its deep commitment to its Health for Humanity 2020 Goals.

There is a growing demand for sustainability strategies in the healthcare ecosystem among U.S. health system executives and operating room clinicians, according to insights from a new JJMDC survey, called the Voices for Value Insights Seriesii. The survey found that nine out of 10 clinicians (92%) and health system executives (88%) agree that sustainability provides long-term cost savings. The majority also agree that sustainability provides additional benefits, such as protecting the environment (76%), improving patient care (73%), and increasing the ability to manage risk and regulatory performance (68%). Nearly all (95%) believe that environmental sustainability contributes to the value of care delivered in their health system. The survey was conducted online between September 7 and 13, 2017 among 92 executives and clinicians at large U.S. health systems.

"Sustainability is critically important to Intermountain Healthcare, but recycling alone is not going to help us reach our goals," said Steve Bergstrom, Director of Sustainability at Intermountain Healthcare. "Our collaboration helps us reduce waste and operating room expenses through a more circular systems approach that is saving hundreds of thousands of dollars on medical device costs and diverting tens of thousands of pounds of Intermountain waste from landfills each year."

The CareAdvantage Sustainability capability enables best-in-class reprocessing across a broad spectrum of product categories, to include both JJMDC as well as non-JJMDC reprocessed single-use devices. It also includes practical tools and educational resources to help health systems create sustainability programs with financial and environmental benefits while implementing best practices for measuring and communicating the value of sustainability in healthcare.

The CareAdvantage Sustainability capability can also help purchasing and sustainability teams in healthcare delivery systems meet their Environmental Preferable Purchasing (EPP) goals. Specific expertise is designed to help healthcare delivery systems build a consistent approach to EPP assessments. In addition, through EARTHWARDS®, the Johnson & Johnson approach for encouraging the development of more sustainable products, health systems can access devices which have been designed with factors such as reducing materials, minimizing packaging, and reducing energy usage in mind.

"Drawing on our extensive experience in sustainability, we can provide health systems with a broad portfolio of sustainably sourced medical devices to help them meet their commitment to environmental stewardship efficiently and cost effectively," said Melinda Thiel, Vice President, Customer Marketing & Solutions at JJMDC. "This is just one element of how we approach customer needs, which starts with listening and leads to a holistic, tailored approach to help them reach their goals and deliver measurable results."

For more information about CareAdvantage and its capabilities, including Sustainability, visit www.careadvantagejjmdc.com. Join the discussion about value-based care on Voices for Value on LinkedIn.

Keywords for this news article include: Environment, Johnson & Johnson Medical Devices Companies.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Science Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:08aJOHNSON & JOHNSON : 's Official Statement in Response to Today's Verdict in St. ..
AQ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19JOHNSON & JOHNSON : Trial Attorneys Willing to Invest Thousands in Upcoming Elec..
AQ
07/19JOHNSON & JOHNSON : Company news in brief
AQ
07/18GERON : Imetelstat Reaffirmed as a Priority for Johnson & Johnson
AQ
07/18JOHNSON & JOHNSON : and picks Penn for research node
AQ
07/18JOHNSON & JOHNSON REPORTS 2018 SECON : 2018 Second-Quarter Sales of $20.8 Billio..
AQ
07/18JOHNSON & JOHNSON : and picks Penn for research-talk hub
AQ
07/18JOHNSON & JOHNSON : Agloan-US Stocks Rebound on Tech, House Goods
AQ
07/18CONFIDANTE OF TAIWAN PRESIDENT TO TA : reports
AQ
More news
News from SeekingAlpha
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19YOUR DAILY PHARMA SCOOP : Tonix Progresses, J&J Succeeds, Quidel Is Cleared 
07/18INTUITIVE SURGICAL : Potentially Attractive Entry Point Following Any Post-2Q18 .. 
Financials ($)
Sales 2018 81 273 M
EBIT 2018 24 895 M
Net income 2018 16 036 M
Debt 2018 12 563 M
Yield 2018 2,79%
P/E ratio 2018 18,60
P/E ratio 2019 16,73
EV / Sales 2018 4,42x
EV / Sales 2019 4,16x
Capitalization 346 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 143 $
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-7.59%346 292
PFIZER3.95%220 236
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225
AMGEN10.87%128 318